Juvenile Macular Degeneration (Stargardt Disease) Market Business Trends, Industry Segments 2027

Global Juvenile Macular Degeneration (Stargardt Disease) Market: Information by Diagnosis (Fluorescein Angiography and others), Management (Magnifying Spectacles and others), End User (Hospital & Eye Clinics and others) and Region - Forecast till 2027

Market Overview

The Global Juvenile Macular Degeneration (Stargardt Disease) Market is expected to register a CAGR of 6.7% and is anticipated to reach USD 1593.885 million by 2027.

Market Highlights

Eye care has become one of the important aspects of medicine due to the continuous development of new therapies and availability of technologically advanced devices for eye care. Furthermore, the prevalence of eye disease is found to be increasing for all ages. Macular degeneration diseases such as Best disease and Stargardt disease are found to be highly prevalent among the children. Market players are now focusing on the development of novel therapies such as stem cell therapy to reduce the supply-demand gap in the market. Eye care supplement act as a protective measure whose demand is found to be increasing in the developing countries across the globe. Additionally, increasing demand for early diagnosis and treatment is boosting the market growth.

Global Juvenile Macular Degeneration (Stargardt Disease) market is expected to grow at a CAGR of 7.2% during the forecast period 2017-2023.

Sample Report: https://www.marketresearchfuture.com/sample_request/4935

The European juvenile macular degeneration market accounted for 32.7% market share in 2016. In Europe, Germany, the U.K, and France are the largest contributors to the market owing to the availability of funds for research, and extensive research and development activities in ophthalmology. The development of novel therapies and other treatment options for juvenile macular degeneration also fuel the growth of the market. The Middle East & Africa exhibit steady but positive growth owing to low technology penetration in developing regions of Africa, and increasing demand for diagnostics services in developing regions. In the Middle East, the United Arab Emirates accounts for the largest market share for macular degeneration.

Key Players in Global Juvenile Macular Degeneration Market Acucela Inc. (U.S.), Alkeus Pharmaceuticals Inc. (U.S.), Astellas Pharma Inc. (Japan), ProQR Therapeutics NV (Netherland), Sanofi (France), Bayer HealthCare (Germany), F. Hoffmann-La Roche (Switzerland), Copernicus Therapeutics Inc. (U.S.), Grupo Ferrer Internacional SA (U.S.), Iris Pharma (U.S.), Nemus Bioscience Inc (U.S.), Ophthotech Corp (U.S.), Iconic Therapeutics (U.S.), Adverum Biotechnologies (U.S.), PanOptica (U.S.), RXi Pharmaceuticals (U.S.), Neurotech Pharmaceuticals (U.S.)

READ MORE @ https://www.marketresearchfuture.com/reports/juvenile-macular-degeneration-market-4935

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

uvenile macular degeneration is a genetic eye disorder that causes progressive vision loss. This disorder affects the retina, the specialized light-sensitive tissue that lines the back of the eye. Specifically, juvenile macular degeneration affects a small area near the center of the retina called the macula. The macula is responsible for sharp central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. The market is mainly driven by factors such as the increasing prevalence of eye disorders, development of new drugs and therapies, and emerging government policies. However, the high cost of treatment and lack of reimbursement is expected to restrain the growth of this market.

uvenile Macular Degeneration Market China and India contribute to the growth of the market. On the other hand, the Middle East & Africa hold the least share of the market due to the low prevalence of macular degeneration in the region and limited availability of funds and availability of medical facilities. The Middle East has a huge share for the Juvenile Macular Degeneration Market due to the presence of well-developed countries like Kuwait, Qatar, Oman and Saudi Arabia. However, due to the presence of a huge opportunity for the development of the market, Africa region is expecting a healthy growth in near future. Global Juvenile Macular Degeneration (Stargardt Disease) market is expected to grow at a CAGR of 7.2% during the forecast period 2017-2023.

Sample Report: https://www.marketresearchfuture.com/sample_request/4935

Key Players in Global Juvenile Macular Degeneration Market Acucela Inc. (U.S.), Alkeus Pharmaceuticals Inc. (U.S.), Astellas Pharma Inc. (Japan), ProQR Therapeutics NV (Netherland), Sanofi (France), Bayer HealthCare (Germany), F. Hoffmann-La Roche (Switzerland), Copernicus Therapeutics Inc. (U.S.), Grupo Ferrer Internacional SA (U.S.), Iris Pharma (U.S.), Nemus Bioscience Inc (U.S.), Ophthotech Corp (U.S.), Iconic Therapeutics (U.S.), Adverum Biotechnologies (U.S.), PanOptica (U.S.), RXi Pharmaceuticals (U.S.), Neurotech Pharmaceuticals (U.S.)